214 related articles for article (PubMed ID: 10617083)
41. Late expression of nitroreductase in an oncolytic adenovirus sensitizes colon cancer cells to the prodrug CB1954.
Lukashev AN; Fuerer C; Chen MJ; Searle P; Iggo R
Hum Gene Ther; 2005 Dec; 16(12):1473-83. PubMed ID: 16390278
[TBL] [Abstract][Full Text] [Related]
42. CB 1954: from the Walker tumor to NQO2 and VDEPT.
Knox RJ; Burke PJ; Chen S; Kerr DJ
Curr Pharm Des; 2003; 9(26):2091-104. PubMed ID: 14529407
[TBL] [Abstract][Full Text] [Related]
43. Development of a Bioluminescent Nitroreductase Probe for Preclinical Imaging.
Vorobyeva AG; Stanton M; Godinat A; Lund KB; Karateev GG; Francis KP; Allen E; Gelovani JG; McCormack E; Tangney M; Dubikovskaya EA
PLoS One; 2015; 10(6):e0131037. PubMed ID: 26110789
[TBL] [Abstract][Full Text] [Related]
44. Engineering
Williams EM; Rich MH; Mowday AM; Ashoorzadeh A; Copp JN; Guise CP; Anderson RF; Flanagan JU; Smaill JB; Patterson AV; Ackerley DF
Biochemistry; 2019 Sep; 58(35):3700-3710. PubMed ID: 31403283
[TBL] [Abstract][Full Text] [Related]
45. Virus-directed enzyme prodrug therapy using CB1954.
Grove JI; Searle PF; Weedon SJ; Green NK; McNeish IA; Kerr DJ
Anticancer Drug Des; 1999 Dec; 14(6):461-72. PubMed ID: 10834268
[TBL] [Abstract][Full Text] [Related]
46. A new 4-nitrobenzyl carbonate prodrug of methyl 5-benzyl-2-hydroxy-11-methylene-6-oxo-5H-benzo[b]carbazole-1-carboxylate for potential use with nitroreductase-based gene-directed enzyme prodrug therapy (GDEPT).
Asche C; Kucklaender U
Pharmazie; 2006 Mar; 61(3):244-5. PubMed ID: 16599269
[TBL] [Abstract][Full Text] [Related]
47. Engineering a Multifunctional Nitroreductase for Improved Activation of Prodrugs and PET Probes for Cancer Gene Therapy.
Copp JN; Mowday AM; Williams EM; Guise CP; Ashoorzadeh A; Sharrock AV; Flanagan JU; Smaill JB; Patterson AV; Ackerley DF
Cell Chem Biol; 2017 Mar; 24(3):391-403. PubMed ID: 28262557
[TBL] [Abstract][Full Text] [Related]
48. Selective cell ablation in transgenic mice expression E. coli nitroreductase.
Clark AJ; Iwobi M; Cui W; Crompton M; Harold G; Hobbs S; Kamalati T; Knox R; Neil C; Yull F; Gusterson B
Gene Ther; 1997 Feb; 4(2):101-10. PubMed ID: 9081700
[TBL] [Abstract][Full Text] [Related]
49. Design and synthesis of novel pyrrolobenzodiazepine (PBD) prodrugs for ADEPT and GDEPT.
Sagnou MJ; Howard PW; Gregson SJ; Eno-Amooquaye E; Burke PJ; Thurston DE
Bioorg Med Chem Lett; 2000 Sep; 10(18):2083-6. PubMed ID: 10999476
[TBL] [Abstract][Full Text] [Related]
50. Expression of the bacterial nitroreductase enzyme in mammalian cells renders them selectively sensitive to killing by the prodrug CB1954.
Bridgewater JA; Springer CJ; Knox RJ; Minton NP; Michael NP; Collins MK
Eur J Cancer; 1995 Dec; 31A(13-14):2362-70. PubMed ID: 8652270
[TBL] [Abstract][Full Text] [Related]
51. Evaluating the abilities of diverse nitroaromatic prodrug metabolites to exit a model Gram negative vector for bacterial-directed enzyme-prodrug therapy.
Chan-Hyams JVE; Copp JN; Smaill JB; Patterson AV; Ackerley DF
Biochem Pharmacol; 2018 Dec; 158():192-200. PubMed ID: 30352235
[TBL] [Abstract][Full Text] [Related]
52. Studies on the nitroreductase prodrug-activating system. Crystal structures of complexes with the inhibitor dicoumarol and dinitrobenzamide prodrugs and of the enzyme active form.
Johansson E; Parkinson GN; Denny WA; Neidle S
J Med Chem; 2003 Sep; 46(19):4009-20. PubMed ID: 12954054
[TBL] [Abstract][Full Text] [Related]
53. Antitumor immune responses mediated by adenoviral GDEPT using nitroreductase/CB1954 is enhanced by high-level coexpression of heat shock protein 70.
Djeha HA; Todryk SM; Pelech S; Wrighton CJ; Irvine AS; Mountain A; Lipinski KS
Cancer Gene Ther; 2005 Jun; 12(6):560-71. PubMed ID: 15665820
[TBL] [Abstract][Full Text] [Related]
54. Expression of Escherichia coli B nitroreductase in established human tumor xenografts in mice results in potent antitumoral and bystander effects upon systemic administration of the prodrug CB1954.
Djeha AH; Hulme A; Dexter MT; Mountain A; Young LS; Searle PF; Kerr DJ; Wrighton CJ
Cancer Gene Ther; 2000 May; 7(5):721-31. PubMed ID: 10830719
[TBL] [Abstract][Full Text] [Related]
55. Dual-therapeutic reporter genes fusion for enhanced cancer gene therapy and imaging.
Sekar TV; Foygel K; Willmann JK; Paulmurugan R
Gene Ther; 2013 May; 20(5):529-37. PubMed ID: 22914496
[TBL] [Abstract][Full Text] [Related]
56. Bacillus amyloliquefaciens orthologue of Bacillus subtilis ywrO encodes a nitroreductase enzyme which activates the prodrug CB 1954.
Anlezark GM; Vaughan T; Fashola-Stone E; Paul Michael N; Murdoch H; Sims MA; Stubbs S; Wigley S; Minton NP
Microbiology (Reading); 2002 Jan; 148(Pt 1):297-306. PubMed ID: 11782522
[TBL] [Abstract][Full Text] [Related]
57. Prodrugs for Nitroreductase Based Cancer Therapy- 1: Metabolite Profile, Cell Cytotoxicity and Molecular Modeling Interactions of Nitro Benzamides with Ssap-NtrB.
Gungor T; Yetis G; Onder FC; Tokay E; Tok TT; Celik A; Ay M; Kockar F
Med Chem; 2018; 14(5):495-507. PubMed ID: 29189173
[TBL] [Abstract][Full Text] [Related]
58. E. coli nitroreductase/CB1954 gene-directed enzyme prodrug therapy: role of arylamine N-acetlytransferase 2.
Mitchell DJ; Minchin RF
Cancer Gene Ther; 2008 Nov; 15(11):758-64. PubMed ID: 18600257
[TBL] [Abstract][Full Text] [Related]
59. Bioreductive prodrug PR-104 improves the tumour distribution and titre of the nitroreductase-armed oncolytic adenovirus ONYX-411
Singleton DC; Mowday AM; Guise CP; Syddall SP; Bai SY; Li D; Ashoorzadeh A; Smaill JB; Wilson WR; Patterson AV
Cancer Gene Ther; 2022 Jul; 29(7):1021-1032. PubMed ID: 34837065
[TBL] [Abstract][Full Text] [Related]
60. Validation of nitroreductase, a prodrug-activating enzyme, mediated cell death in embryonic zebrafish (Danio rerio).
Pisharath H
Comp Med; 2007 Jun; 57(3):241-6. PubMed ID: 17605338
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
